The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Eli Lilly valuation debate returns as investors weigh rapid growth against a higher intrinsic value estimate
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 17, 11:45 AM EDT

Eli Lilly valuation debate returns as investors weigh rapid growth against a higher intrinsic value estimate

A market commentary points to an updated Discounted Cash Flow view that, even after a steep run, implies Eli Lilly’s shares could still be trading below an estimated intrinsic value.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly’s stock has surged over the past several years, and a fresh valuation question is now circulating among market watchers: is the rally already “priced in,” or does the company’s growth still leave room for shares to look inexpensive versus an intrinsic value estimate?

In a report carried by Yahoo Finance, the argument for potential undervaluation is built around a Discounted Cash Flow (DCF) framework. A DCF model attempts to estimate what a firm’s future cash flows are worth today by projecting cash generation and discounting it back to a present-value figure. The commentary suggests that, under its assumptions, the DCF-implied value remains meaningfully above the stock’s prevailing market price.

The article frames the debate in terms of where the shares trade relative to the model’s estimate. It notes that Lilly’s stock is changing hands around $1,180 per share following what it describes as a very strong five-year run, and it contrasts that market level with its view of a higher intrinsic value derived from DCF math.

The commentary, however, does not supply the full set of model inputs in the material referenced here, nor does it detail Lilly’s specific cash-flow projections, discount rate, or long-term margin assumptions. It also does not break out scenario analysis (such as bull and bear cases) in the excerpted description. As a result, readers are left with a conclusion that depends heavily on assumptions that are not visible in the available text.

Even so, the broader market context is familiar. For large-cap biopharma companies, valuation discussions often turn on whether growth is likely to remain durable enough to justify elevated expectations. Lilly’s recent performance has contributed to a sense among investors that future cash generation could stay resilient, but the same momentum can also make DCF work more sensitive to changes in growth rates and profitability over time.

What is clear from the referenced commentary is the thrust of the thesis: if Lilly continues to deliver growth, the DCF estimate used by the writer can still land above the current share price, implying the stock may be undervalued. What remains uncertain in the cited description is exactly how much the valuation gap depends on the model’s assumptions, and whether the implied upside would persist under alternate projections or if growth slows from the pace that has supported the stock’s run.

Why It Matters

  • DCF-based debates can quickly shift investor sentiment for large pharma names because valuation is sensitive to assumptions about long-term cash generation.
  • After a multi-year rally, even small changes in expected growth can widen or narrow the gap between intrinsic value estimates and market prices.
  • If the model’s assumptions hold, the thesis supports the idea that Lilly’s stock may still have room relative to intrinsic value, but the outcome depends on the full set of inputs not shown in the excerpt.

Sources

Key Facts

  • The Yahoo Finance piece frames its valuation view using a Discounted Cash Flow (DCF) approach, which estimates intrinsic value by discounting projected future cash flows.
  • The commentary says Eli Lilly’s intrinsic value estimate sits meaningfully above the stock’s market price.
  • It notes Lilly shares are trading around $1,180 per share after a very strong five-year run.
  • The available description emphasizes the “growth keeps delivering” premise behind the undervaluation argument.
  • The referenced description does not provide the specific DCF inputs such as cash-flow projections, discount rate, or scenario ranges.

Healthcare Related

Eli Lilly valuation debate returns as investors weigh rapid growth against a higher intrinsic value estimate | The Apex Times